(Reuters) -Amgen on Tuesday said its adjusted fourth-quarter profit rose 15%, driven by a 20% increase in revenue following the biotechnology company's October acquisition of rare disease drugmaker Horizon Therapeutics. For full-year 2024, the company said it expects adjusted earnings per share of $18.90 to $20.30 on revenue of $32.4 billion to $33.8 billion. "The guidance looks good and in line with consensus," Jefferies analyst Michael Yee said in an email.
Gilead Sciences on Tuesday said fourth-quarter revenue dipped 4% on lower sales of HIV drugs and its infused COVID-19 treatment Veklury, and the company forecast weaker-than-expected 2024 sales. For full-year 2024, Gilead said it expects adjusted earnings of $6.85 to $7.25 per share on product sales of $27.1 billion to $27.5 billion. Analysts have projected 2024 earnings of $7.24 per share on revenue of $27.7 billion.
(Reuters) -Amgen on Tuesday said its adjusted fourth-quarter profit rose 15%, driven by a 20% increase in revenue following the biotechnology company's October acquisition of rare disease drugmaker Horizon Therapeutics. For full-year 2024, the company said it expects adjusted earnings per share of $18.90 to $20.30 on revenue of $32.4 billion to $33.8 billion. "The guidance looks good and in line with consensus," Jefferies analyst Michael Yee said in an email.
By Michael Erman and Deena Beasley NEW YORK (Reuters) -The U.S. Food and Drug Administration has been looking into 22 cases of T-cell cancers that occurred .
(Reuters) -Gilead Sciences said on Monday its drug, Trodelvy, failed to significantly improve survival for previously treated patients with advanced non-small cell lung cancer (NSCLC) in a late-stage study, sending its shares down more than 10%. The California-based drugmaker was testing Trodelvy, which belongs to a class of treatments known as antibody drug conjugates, in patients with both squamous and non-squamous NSCLC - the most common type of lung cancer. Roughly 230,000 adults in the United States were estimated to be diagnosed with lung cancer in 2023, and NSCLC accounts for 81% of all those diagnoses, according to the American Society of Clinical Oncology.